Shares of Oramed Pharmaceuticals (NASDAQ: ORMP) were on an upswing in pre-market trading on Friday as the clinical-stage pharmaceutical company announced additional positive data from its Phase 2 study of its oral insulin candidate (ORMD-0801).
This Phase 2 study was a double-blind, fully randomized, placebo-controlled, multicenter clinical trial (ORA-D-N02) to assess the safety and efficacy of ORMD-0801 when it comes to the reduction of liver fat content in Type 2 Diabetes patients with non-alcoholic steatohepatitis (NASH).
This study indicated that ORMD-0801 achieved the primary endpoint of safety and tolerability and the oral insulin candidate achieved “consistent trends across key secondary endpoints with reduction of liver fat, liver stiffness and lipids.”
Earlier this week, the company also announced that it has entered into an exclusive commercial distribution agreement with Medicox for ORMD-0801.
